Patents by Inventor Rolf Krauss
Rolf Krauss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11988544Abstract: The invention relates to a method for weighing pharmaceutical containers (10) nested in a carrier (11), in which at least one of the nested containers (10) is weighed by means of a weighing device (1), wherein a relative movement between the at least one pharmaceutical container (10) and the carrier (11) is brought about in order to release the pharmaceutical containers (10) from the carrier (11) in order to increase the weighing accuracy.Type: GrantFiled: September 18, 2019Date of Patent: May 21, 2024Assignees: Syntegon Technology GmbH, Syntegon Packaging Systems AG, Syntegon Packaging Technology GmbHInventors: Philipp Roth, Ulrich Krauß, Klaus Ullherr, Tim Fleckenstein, Rolf Barthelmess, Martin Maerz, Thomas Beck, Ralf Riebeling, Heiko Wild, Joachim Radtke, Jochen Peters, Oliver Gerundt, Harald Ott, Olaf Eistert, Frank Scholl, Herbert Schaffert, Jochen Lautenschlager, Paul Mehringer, Faruk Civelek
-
HDAC INHIBITOR IN COMBINATION WITH VEGF/VEGFR INTERACTION FOR CANCER THERAPY BASED ON PLATELET COUNT
Publication number: 20200016118Abstract: The invention relates to methods, composition and uses for the of treatment of cancer selected from the group consisting of HCC, RCC, NSCLC, ovarian cancer, CCA, PTC and FTC in a subject, which comprise administering an HDAC inhibitor in combination with a compound inhibiting the VEGF/VEGFR interaction, wherein said subject is characterized in having a platelet count of about 140000 platelets/?l or higher.Type: ApplicationFiled: April 5, 2017Publication date: January 16, 2020Applicants: 4SC AG, Yakult Honsha Co., Ltd.Inventors: Rolf KRAUSS, Takuya KIMURA, Masatoshi KUDO -
Patent number: 8227516Abstract: The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.Type: GrantFiled: July 16, 2007Date of Patent: July 24, 2012Assignee: 4SC Discovery GmbHInventors: Alexander B. Maurer, Sascha Hoevelmann, Elke Martin, Bernd Hentsch, Michael Gassen, Juergen Kraus, Rolf Krauss, Adam-Spencer Vincek
-
Publication number: 20110172241Abstract: The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents —Y are attached to the 5- or 6-position of the benzazole.Type: ApplicationFiled: March 23, 2011Publication date: July 14, 2011Applicant: 4SC AGInventors: Thomas HERZ, Rolf KRAUSS, Michael KUBBUTAT, Martin LANG, Christoph SCHAECHTELE, Stefan TASLER, Frank TOTZKE
-
Publication number: 20090270410Abstract: The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents -Y are attached to the 5- or 6-position of the benzazole.Type: ApplicationFiled: July 7, 2009Publication date: October 29, 2009Applicant: 4SC AGInventors: Thomas HERZ, Rolf KRAUSS, Michael KUBBUTAT, Martin LANG, Christoph SCHAECHTELE, Stefan TASLER, Frank TOTZKE
-
Patent number: 7576090Abstract: The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents —Y are attached to the 5- or 6-position of the benzazole.Type: GrantFiled: December 22, 2005Date of Patent: August 18, 2009Assignee: 4SC AGInventors: Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Christoph Schaechtele, Stefan Tasler, Frank Totzke
-
Patent number: 7514460Abstract: The present invention relates to N2-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.Type: GrantFiled: December 15, 2005Date of Patent: April 7, 2009Assignee: 4SC AGInventors: Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Christoph Schaechtele, Stefan Tasler, Frank Totzke
-
Publication number: 20090088478Abstract: The present invention relates to compounds as inhibitors of enzymes having histone deacetylase activity, to the processes for the preparation of those compounds, and to their use for the treatment of diseases which are associated with hypoacetylation of histones and/or other molecules, or in which induction of hyperacetylation has a beneficial effect for example by inhibition of proliferation and/or induction of differentiation and/or induction of apoptosis in transformed cells, such as cancer. Furthermore, the compounds are useful for the treatment of other proliferative diseases, for therapy or prophylaxis of conditions associated with abnormal gene expression.Type: ApplicationFiled: July 16, 2007Publication date: April 2, 2009Inventors: Alexander B. Maurer, Sascha Hoevelmann, Elke Martin, Bernd Hentsch, Michael Gassen, Juergen Kraus, Rolf Krauss, Adam-Spencer Vincek
-
Publication number: 20070149523Abstract: Compounds of formula (I) and salts and physiologically functional derivatives thereof, wherein R2 is attached at the 4- or 5-position of the thiazole ring and is hydrogen, alkyl, halogen, cyano, alkoxy, haloalkoxy, or alkylamino; X independently represents a divalent linkage group selected from S, O, NR4, SO, or SO2; R4 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, or heterocyclyl; R1 is attached at the 4- or 5-position of the thiazole ring and independently represents a group of formula (II): ?wherein the dotted line represents a single or double bond; * indicates the point of attachment to the thiazole ring; and n is 1, 2, or 3. Also disclosed are pharmaceutical compositions comprising the above compounds and method of treatments for cancer and other diseases.Type: ApplicationFiled: November 14, 2006Publication date: June 28, 2007Inventors: Jan Ehlert, Thomas Herz, Rolf Krauss, Micheal Kubbutat, Martin Lang, Stefano Pegoraro, Christoph Schachtele, Frank Totzke, Ute Zirrgiebel
-
Publication number: 20070021446Abstract: The present invention relates to compounds of the general formula (I) and salts, prodrugs, and stereoisomers thereof, wherein Y independently represents S, O, NR2, SO, SO2; A independently represents a fife- or six-membered aromatic carbocycle or heterocycle and wherein R1 to R20 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties.Type: ApplicationFiled: May 16, 2006Publication date: January 25, 2007Applicant: 4SC AGInventors: Jan Ehlert, Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Wael Saeb, Christoph Schaechtele, Stefan Tasler, Frank Totzke, Ute Zirrgiebel
-
Publication number: 20060142570Abstract: The present invention relates to compounds of the general formulas (I), (Ia) and (II) and salts and physiologically functional derivatives thereof, wherein the substituents —Y are attached to the 5- or 6-position of the benzazole.Type: ApplicationFiled: December 22, 2005Publication date: June 29, 2006Applicant: 4SC AGInventors: Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Christoph Schaechtele, Stefan Tasler, Frank Totzke
-
Publication number: 20060135782Abstract: The present invention relates to N2-heteroaryl-benzazole-2,(5 or 6)-diamine derivatives and compositions thereof as protein kinase inhibitors for the treatment of e.g. cancer.Type: ApplicationFiled: December 15, 2005Publication date: June 22, 2006Applicant: 4SC AGInventors: Thomas Herz, Rolf Krauss, Michael Kubbutat, Martin Lang, Christoph Schaechtele, Stefan Tasler, Frank Totzke
-
Patent number: 6949567Abstract: The invention relates to new diphenylurea having the formula (I) or a salt thereof, where Y is C?O, C?S, C?NH, (C?O)2 or SO2; and to processes for the preparation of these compounds and to their use in the treatment of protozoal diseases and to diseases where the inhibition of intracellular protein-degradation pathways is of benefit.Type: GrantFiled: February 26, 2002Date of Patent: September 27, 2005Assignee: 4SC AGInventors: Andrea Aschenbrenner, Katharina Aulinger Fuchs, Matthias Dormeyer, Gabriel Garcia, Bernd Kramer, Jürgen Kraus, Rolf Krauss, Johan Leban, Stefano Pegoraro, Wael Saeb, Kristina Wolf
-
Publication number: 20050176686Abstract: The present invention is directed to compounds of the general formula (I) or pharmaceutical acceptable salts or physiologically functional derivatives thereof wherein: n is a non-aromatic ring system containing two to seven carbon atoms, wherein the ring system can contain one ore two double bonds; X is C, CH or CH2; Y is selected from C, CH, CH2, S, NR, CH2-CH2, H2C—CH, HC—CH2, C—CH2, H2C—C, or C—C; one or more of the hydrogen atoms can optionally be substituted by one or more substituents R?; each of the dotted lines means a single, a double or triple bond with the exclusion of a combination of a triple with triple bond and a double with a triple bond; R? is independently H, —CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogene, haloalkyl, haloalkyloxy; R is H, an alkyl or cycloalkyl group; Z is CH, C, or P; p is 0 or 1.Type: ApplicationFiled: July 23, 2003Publication date: August 11, 2005Applicants: 4SC AG, G2M Cancer Drugs AGInventors: Alexander Maurer, Sascha Hoevelmann, Elke Martin, Bernd Hentsch, Michael Gassen, Juergen Kraus, Rolf Krauss, Adam-Spencer Vincek
-
Publication number: 20050143382Abstract: The present invention relates to furazanopyrazine derivatives of the general formula (I): wherein: R? represents —NR1R2 or —OR9 R? represents —NR5—NR3R4, —NR5—ORb, —O—NR3R4; wherein R1 to R9 in formula (I) represent independently of each other a variety of different substituents comprising alkyl, aryl, aralkyl, alkylaryl, heteroaryl groups and monofunctional moieties.Type: ApplicationFiled: November 2, 2004Publication date: June 30, 2005Applicant: 4SC AGInventors: Katharina Aulinger-Fuchs, Thomas Herz, Rolf Krauss, Michael Kubbatat, Martin Lang, Christoph Schachtele, Frank Totzke
-
Publication number: 20030119876Abstract: The invention relates to new diphenylurea having the formula (I) 1Type: ApplicationFiled: February 26, 2002Publication date: June 26, 2003Inventors: Andrea Aschenbrenner, Katharina Aulinger Fuchs, Matthias Dormeyer, Gabriel Garcia, Bernd Kramer, Jurgen Kraus, Rolf Krauss, Johan Leban, Stefano Pegoraro, Wael Saeb, Kristina Wolf
-
Publication number: 20020165236Abstract: Treatment of Protozoan Infections with new diphenylurea derivatives.Type: ApplicationFiled: December 12, 2001Publication date: November 7, 2002Inventors: Andrea Aschenbrenner, Katharina Aulinger Fuchs, Matthias Dormeyer, Gabriel Garcia, Bernd Kramer, Stefano Pegoraro, Jurgen Kraus, Rolf Krauss, Hans Leban, Wael Saeb, Kristina Wolf